RxDoctor Payments Data

Elvia Canseco, MD

Ophthalmology · Houston, TXNPI 1124282983

Payments from drug & device makers

$322,320in general payments, 2019–2025

Across 440 payments — averaging $732.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$262K
  • Sun Pharmaceutical Industries Inc.$37K
  • Glaukos Corporation$15K
  • AbbVie$3K
  • Bausch & Lomb Americas Inc.$2K
  • Alcon$633
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$48,36115%
  • Speaking & faculty fees$222,43269%
  • Travel & lodging$35,38711%
  • Food & beverage$16,1405%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$322,320 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$27,775
Medicare patients
52
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner502$983,721
RestasisCyclosporine60$73,558
LumiganBimatoprost97$45,577
Cyclosporine17$10,082
Prednisolone Acetate223$7,445
MoxifloxacinMoxifloxacin Hcl175$5,463
Ketorolac Tromethamine139$3,431
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$3,377
Bromfenac Sodium14$2,221
ValacyclovirValacyclovir Hcl13$676
Azelastine Hcl16$660
Latanoprost66$656
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$332
Timolol Maleate17$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$262,483$983,721502 claims
AbbVieRestasis, Lumigan$2,594$119,135157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →